The FDA-approved weight loss pill is here
No injections. Just once-daily Wegovy® with proven results—up to 17% average weight loss in trials.
Rybelsus is the only FDA-approved oral semaglutide tablet. It treats type 2 diabetes in adults and contains the same active ingredient as Ozempic and Wegovy — but as a once-daily pill rather than a once-weekly injection. Oral semaglutide is convenient, but it requires strict timing on an empty stomach and produces somewhat smaller A1C and weight changes than injectable semaglutide at standard doses.1,3,4
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a gut hormone that boosts insulin release after meals, slows stomach emptying, and signals fullness to the brain. Rybelsus is the only FDA-approved oral formulation; it pairs semaglutide with a permeation enhancer (SNAC) that helps the drug cross the stomach lining.1,2
Ozempic and Wegovy are the same molecule in injectable form. Ozempic is approved for type 2 diabetes and cardiovascular risk reduction; Wegovy is approved for chronic weight management.3
Rybelsus is FDA-approved for adults with type 2 diabetes, used along with diet and exercise to improve blood sugar control. It is not approved for:1
Like other GLP-1s, Rybelsus carries a boxed warning about thyroid C-cell tumors observed in rodents. It should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.1
Dosing follows a step-up schedule, with at least 30 days between each step:1
Strict administration rules — these matter for absorption:1,5
The injectable form is somewhat more effective at standard doses:4
For some patients — especially those uncomfortable with injections or who prefer daily dosing — oral semaglutide is the better fit. Others benefit from the larger A1C and weight changes of the injectable.
GI symptoms are most common during dose escalation and usually improve over four to eight weeks.5
Avoid Rybelsus if you have:1
Tell your clinician if you're pregnant, planning to become pregnant, or breastfeeding. Semaglutide should generally be stopped at least two months before a planned pregnancy.
Starting or switching GLP-1 therapy works best with a clinician who can confirm the right diagnosis, document for prior authorization, and walk you through dose escalation. If you don't have a primary care provider or need a same-day visit to start the conversation, you can find primary care and urgent care visits on Solv. For acute side effects — severe abdominal pain, persistent vomiting, or signs of dehydration — go to urgent care or the ER.
No. Rybelsus is approved only for adults with type 2 diabetes. Off-label prescribing for weight loss occurs, but insurance rarely covers it for that indication. Wegovy (injectable semaglutide) is the FDA-approved option for weight loss.1,3
The tablet contains a permeation enhancer that helps semaglutide cross the stomach lining, but food, other liquids, or other oral medications interfere with absorption. The FDA label requires no more than 4 ounces of plain water, 30 minutes before anything else.1
Both contain semaglutide. Once-weekly injectable semaglutide at 1.0 mg reduces A1C by about 1.5 to 1.8 percentage points; oral semaglutide 14 mg reduces A1C by about 1.0 to 1.4 percentage points. Real-world data is more mixed and depends heavily on consistent dosing.4
Less than with injectable semaglutide. In head-to-head studies, injectable semaglutide produces greater weight reduction than the 14 mg oral dose. Individual results vary widely based on dose, duration, diet, and activity.4
Skip the missed dose and take the next dose at your usual time the next day. Don't double up. If you miss two or more consecutive doses, talk to your prescriber — restarting may require dose adjustment.5
Not without prescriber input. The conversions are not 1:1 by milligram, and switching requires re-titration. Your clinician will choose based on your tolerance, preference, blood sugar response, and insurance coverage.
No injections. Just once-daily Wegovy® with proven results—up to 17% average weight loss in trials.